Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2017

Feb 01, 2018

SELL
$137.28 - $155.55 $23.8 Million - $26.9 Million
-173,157 Closed
0 $0
Q3 2017

Oct 23, 2017

BUY
$148.13 - $162.24 $8.39 Million - $9.19 Million
56,646 Added 48.62%
173,157 $26.3 Million
Q2 2017

Aug 10, 2017

BUY
N/A
116,511
116,511 $15 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $120B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Nationwide Fund Advisors Portfolio

Follow Nationwide Fund Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nationwide Fund Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Nationwide Fund Advisors with notifications on news.